Paul V. Licciardi, Australia
Murdoch Children's Research Institute Infection and ImmunityPresenter of 1 Presentation
INCREASED PCV10 IMMUNOGENICITY FOLLOWING A TWO-DOSE PRIMARY SERIES SEPARATED BY 4 MONTHS COMPARED WITH 2 MONTHS IN VIETNAMESE INFANTS (ID 963)
- Paul V. Licciardi, Australia
- Beth Temple, Australia
- Dai V. Trang, Australia
- Trong Toan Nguyen, Viet Nam
- Uyen Y. Doan, Viet Nam
- Cattram D. Nguyen, Australia
- Thanh V. Phan, Viet Nam
- Kathryn Bright, Australia
- Rachel A. Marimla, Australia
- Anne Balloch, Australia
- Tran Ngoc Huu, Viet Nam
- Kim E. Mulholland, Australia
Author Of 7 Presentations
INCREASED PCV10 IMMUNOGENICITY FOLLOWING A TWO-DOSE PRIMARY SERIES SEPARATED BY 4 MONTHS COMPARED WITH 2 MONTHS IN VIETNAMESE INFANTS (ID 963)
- Paul V. Licciardi, Australia
- Beth Temple, Australia
- Dai V. Trang, Australia
- Trong Toan Nguyen, Viet Nam
- Uyen Y. Doan, Viet Nam
- Cattram D. Nguyen, Australia
- Thanh V. Phan, Viet Nam
- Kathryn Bright, Australia
- Rachel A. Marimla, Australia
- Anne Balloch, Australia
- Tran Ngoc Huu, Viet Nam
- Kim E. Mulholland, Australia
COMPARISON OF A 2+1 AND 3+0 SCHEDULE OF PCV10 IN VIETNAM (ID 1035)
- Beth Temple, Australia
- Paul V. Licciardi, Australia
- Vo Thi Trang Dai, Viet Nam
- Trong Toan Nguyen, Viet Nam
- Doan Y. Uyen, Viet Nam
- Cattram D. Nguyen, Australia
- Thanh V. Phan, Viet Nam
- Hoan Thi Pham, Viet Nam
- Kathryn Bright, Australia
- Rachel A. Marimla, Australia
- Monica L. Nation, Australia
- Belinda D. Ortika, Australia
- Catherine Satzke, Australia
- Heidi Smith-Vaughan, Australia
- Anne Balloch, Australia
- Tran Ngoc Huu, Viet Nam
- Edward K. Mulholland,
HEAD TO HEAD COMPARISONS AT 2, 4, AND 7 MONTHS, FOLLOWING STANDARD AND COMBINED PHID-CV10 AND PCV13 SCHEDULES. (ID 429)
- Amanda J. Leach, Australia
- Nicole Wilson, Australia
- Jemima Beissbarth, Australia
- Kim E. Mulholland, Australia
- Mathuram Santosham, United States of America
- Peter McIntyre, Australia
- Paul V. Licciardi, Australia
- Mark Chatfield, Australia
- Victor Oguoma, Australia
- Jonathan Carapetis, Australia
- Sue Skull, Australia
- Heidi Smith-Vaughan, Australia
- Vicki Krause, Australia
- Ross Andrews, Australia
- Peter Morris, Australia
- Paul Torzillo, Australia
Abstract
Background
Australian Aboriginal children are at high risk of early infection withStreptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi). We evaluated immunogenicity against 10 shared serotypes of a 4-dose combination schedule of PHiD-CV10 at 1-2-4 months plus PCV13 at 6 months, compared with standard 2-4-6 month schedules.
Methods
Infants were allocated (1:1:1) at 28 to 38 days of age, to 3-dose schedules of PCV13 (P) or PHiD-CV10 (S) at 2-4-6 months (_PPP or _SSS), or a combination schedule at 1-2-4-6 months (SSSP). Immunogenicity was measured at 2, 4, and 7 months.
Results
At 2 months the SSSP combination was superior to pre-vaccination (VTs other than 6B, 19F, or 23F). At 4 months SSSP was superior to _PPP (9 VTs) and _SSS (7 VTs), and _SSS was superior to _PPP (8 VTs). At 7 months, SSSP was superior to _PPP (1, 6B, 9V, 19F and 23F) and _SSS (8 VTs), and _PPP was superior to _SSS (8 VTs). OPA supports the SSSP schedule, particularly against 1, 6B, and 23F.
Conclusions
The 1-2-4-6 month schedule (SSSP) was superior at 2, 4, and 7 months of age compared to _SSS or _PPP, particularly for 1, 6B, and 23F at 7 months. At 4 months, _SSS was superior to _PPP.
IMMUNOGENICITY OF A SINGLE DOSE OF PCV10 GIVEN AT 18 MONTHS OF AGE AND IMPACT ON NASOPHARYNGEAL CARRIAGE IN VIETNAMESE CHILDREN (ID 735)
- Rachel A. Marimla, Australia
- Beth Temple, Australia
- Thi Trang Dai Vo, Viet Nam
- Thanh V. Phan, Viet Nam
- Trong Toan Nguyen, Viet Nam
- Leena Spry, Australia
- Monica L. Nation, Australia
- Belinda D. Ortika, Australia
- Doan Y. Uyen, Viet Nam
- Cattram D. Nguyen, Australia
- Kathryn Bright, Australia
- Anne Balloch, Australia
- Huu T. Ngoc, Viet Nam
- Kim E. Mulholland, Australia
- Catherine Satzke, Australia
- Paul V. Licciardi, Australia
IMMUNOGENICITY OF A SINGLE DOSE OF PCV10 OR PCV13 AT 2 MONTHS OF AGE IN VIETNAM (ID 1007)
Abstract
Background
A 1+1 pneumococcal conjugate vaccine (PCV) schedule would increase its affordability for low and middle-income countries. The Vietnam Pneumococcal Trial II includes infants randomised to receive a 1+1 schedule of PCV10 or PCV13 at 2 and 12 months of age. This study measured the immunogenicity of a single dose of either PCV given at 2 months of age.
Methods
Serotype-specific IgG was measured at 3 and 12 months of age in PCV-vaccinated and unvaccinated controls using a WHO ELISA method.
Results
At 3 months, both vaccinated groups had higher antibody levels than controls for 7/10 serotypes (all except 6B, 14, 23F). The PCV10 group had higher antibody levels than the PCV13 group for 5/10 serotypes. Similar results were seen at 12 months, with higher antibody levels for all serotypes in the PCV10 group and 8/10 serotypes (all except 6V, 23F) in the PCV13 group compared with controls and higher antibody levels in the PCV10 than the PCV13 group for 7/10 serotypes.
Conclusions
A single dose of PCV in infancy is immunogenic and likely to provide some direct protection until the time of the booster dose. There may be a difference in the degree of protection offered by different PCVs.
INTERCHANGEABILITY OF PHID-CV10 AND PCV13 IN PRIMARY COURSE SCHEDULES (ID 204)
- Amanda J. Leach, Australia
- Nicole Wilson, Australia
- Jemima Beissbarth, Australia
- Kim E. Mulholland, Australia
- Mathuram Santosham, United States of America
- Peter McIntyre, Australia
- Paul V. Licciardi, Australia
- Mark Chatfiled, Australia
- Victor Oguoma, Australia
- Jonathan Carapetis, Australia
- Sue Skull, Australia
- Heidi Smith-Vaughan, Australia
- Vicki Krause, Australia
- Ross Andrews, Australia
- Peter Morris, Australia
- Paul Torzillo, Australia
Abstract
Background
In remote communities of northern Australia, we previously demonstrated that the onset of otitis media (OM) in Aboriginal infants was preceded by acquisition of bacterial pathogens that colonise the nasopharynx (NP) soon after birth. We aimed to determine safety and effectiveness of mixed vaccine schedules against early infection due to non-typeable Haemophilus influenzae and Streptococcus pneumoniae.
Methods
In an open-label controlled trial, we randomised (1:1:1) Aboriginal infants at 28 to 38 days of age, to either Prevenar13™ (P, PCV13) at 2-4-6 months of age (_PPP), Synflorix™ (S, PHiD-CV10) at 2-4-6 months (_SSS), or Synflorix at 1-2-4 months plus Prevenar13 at 6 months (SSSP). Primary outcomes (assessor-blinded) were immunogenicity at 7 months of age against pneumococcal serotypes 3, 6A, and 19A, and protein D (GMCs and proportions of infants with IgG > 0·35 µg/mL or > 100 EL.U/mL, respectively). Secondary immunogenicity outcomes at 2 and 4 months are also reported.
Results
A 4-dose early 1-2-4-6 month combination schedule of Synflorix plus Prevenar13 (SSSP) provided superior overall immune protection against serotypes 3, 6A, 19A, and protein D, compared to standard 3-dose 2-4-6 month schedules (_SSS or _PPP).
Conclusions
These vaccines can be combined safely and effectively within this primary schedule, with no evidence of immune suppression.